The article discusses the landscape of ADR stocks, focusing on Immatics (NASDAQ:IMTX), a German biopharmaceutical company specializing in cancer immunotherapy. Despite being shorted, the company shows promise with positive clinical trial results and strong hedge fund interest.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing